We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.49B
AUM Growth
-$101M
Cap. Flow
+$10.3M
Cap. Flow %
0.69%
Top 10 Hldgs %
30.22%
Holding
143
New
5
Increased
56
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$24.2M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$11.2M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.9M
5
MRK icon
Merck
MRK
+$9.97M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.8M
2
HCA icon
HCA Healthcare
HCA
+$32.5M
3
MCK icon
McKesson
MCK
+$13.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.83M
5
GI
EndoChoice Holdings, Inc.
GI
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.35%
2 Financials 4.56%
3 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
76
Kyntra Bio
KYNB
$29.4M
$5.14M 0.34%
9,600
+260
+3% +$130K
CLVS
77
DELISTED
Clovis Oncology, Inc.
CLVS
$4.89M 0.33%
110,000
-15,000
-12% -$528K
MEDP icon
78
Medpace
MEDP
$16.5B
$4.87M 0.33%
135,000
– –
ASMB icon
79
Assembly Biosciences
ASMB
$529M
$4.74M 0.32%
32,500
– –
KDNY
80
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.73M 0.32%
83,000
– –
MGNX icon
81
MacroGenics
MGNX
$257M
$4.6M 0.31%
225,000
– –
STE icon
82
Steris
STE
$23.1B
$4.38M 0.29%
65,000
+25,000
+63% +$1.7M
CGEN icon
83
Compugen
CGEN
$228M
$4.21M 0.28%
825,000
– –
XENT
84
DELISTED
Intersect ENT, Inc
XENT
$4.17M 0.28%
345,000
– –
NVDQ
85
DELISTED
Novadaq Technologies Inc.
NVDQ
$3.94M 0.26%
555,000
– –
AGN.PRA
86
DELISTED
Allergan plc
AGN.PRA
$3.82M 0.26%
5,000
– –
ALDR
87
DELISTED
Alder Biopharmaceuticals
ALDR
$3.79M 0.25%
182,000
– –
FOLD
88
DELISTED
Amicus Therapeutics
FOLD
$3.77M 0.25%
757,500
+62,500
+9% +$433K
JUNO
89
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.71M 0.25%
197,001
– –
INVA icon
90
Innoviva
INVA
$1.48B
$3.6M 0.24%
336,900
– –
KITE
91
DELISTED
Kite Pharma, Inc.
KITE
$3.54M 0.24%
79,000
– –
OTIC
92
DELISTED
Otonomy, Inc.
OTIC
$3.34M 0.22%
210,000
– –
CORV
93
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$3.31M 0.22%
1,200,000
– –
NBRV
94
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.12M 0.21%
2,100
+396
+23% +$526K
CDTX
95
DELISTED
Cidara Therapeutics
CDTX
$3.12M 0.21%
15,000
+2,500
+20% +$520K
ARIA
96
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.11M 0.21%
250,000
+225,000
+900% +$2.71M
PBYI icon
97
Puma Biotechnology
PBYI
$454M
$2.9M 0.19%
94,500
+25,000
+36% +$1.08M
ITCI
98
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.87M 0.19%
190,000
– –
TTPH
99
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.81M 0.19%
34,900
+1,775
+5% +$140K
ADAP
100
DELISTED
Adaptimmune Therapeutics
ADAP
$2.73M 0.18%
675,000
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rock Springs Capital Management held 143 positions worth $1.49B, down 6.3% from $1.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2016 filing shows 5 new, 56 increased, 18 reduced and 10 closed positions. Its largest new stake was UnitedHealth: 165,000 shares worth $26.4M. The largest sale was Pfizer, an estimated $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2016 buy was UnitedHealth: 165,000 shares worth $26.4M.
  • Rock Springs Capital Management added most to Alexion Pharmaceuticals in Q4 2016, an estimated $24.2M increase.
  • Rock Springs Capital Management's biggest Q4 2016 reduction was Gilead Sciences, cutting an estimated $5.02M.
  • Rock Springs Capital Management fully exited Pfizer in Q4 2016, selling an estimated $35.8M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $1.49B portfolio in Q4 2016.
  • Rock Springs Capital Management opened 5 new positions and closed 10 in Q4 2016.
  • Rock Springs Capital Management's portfolio value fell 6.3% quarter-over-quarter to $1.49B.

Based on Rock Springs Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.